IP Library Granted Patent US 11,903,925
Granted Patent B2
US 11,903,925 · App. 16/162,222 · Granted Feb 20, 2024

Compositions for preventing and treating pulmonary injury due to ionizing radiation or cytotoxic drugs

Inventor: Lars Otto Uttenthal (Madrid, ES)
Assignee: RepoCeuticals A/S
A61K31/4045A61K9/0073A61K31/122A61K31/355A61K31/375A61K31/385
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,903,925
App. No.
16/162,222
Granted
Feb 20, 2024
Kind
B2
Abstract

Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.

Claims (13)

1. A method for the treatment of lung damage due to chest irradiation, said method comprising:

providing a composition comprising a micronized powder, which comprises melatonin, to a patient, wherein:

said patient is selected as having a primary or secondary cancer of the chest and is to receive external beam radiotherapy with a total radiation dose in the range of 2-70 GY;

said selected patient receives said composition via intratracheal, intrabronchial, or bronchoalveolar inhalation no more than 15 minutes before each dose of said radiotherapy;

said micronized powder comprises a sugar excipient and particles having an aerodynamic diameter of 2 μm to 5 μm; and

the dosage of melatonin administered is in the range of 5-20 mg per inhalation.

2. The method of treatment according to claim 1 , wherein the sugar excipient is lactose, mannitol, or xylitol.

3. The method according to claim 1 , wherein the composition is administered 1, 2, 3, 4, 5, or 6 times per day.

4. The method according to claim 1 , wherein the composition is administered over a period of up to 3 months or more.

5. The method according to claim 1 , wherein a single dose of the composition administered comprises a dose of melatonin of 15 μg to 300 μg per kilogram of body weight.

6. The method according to claim 1 , wherein the single standard adult dose of melatonin is 1 mg to 20 mg.

7. The method according to claim 1 , wherein the total daily dose of melatonin is from one to six times the single dose of 15 μg to 300 μg per kilogram of body weight.

8. The method according to claim 1 , wherein a single dose of melatonin is administered immediately before an episode of irradiation and each night before retiring.

Assignments (2)
CHANGE OF NAME Recorded Aug 12, 2021
From: REPOCEUTICALS APS
To: REPOCEUTICALS A/S
Reel/Frame 057182/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2018
From: UTTENTHAL, LARS OTTO
To: REPOCEUTICALS APS
Reel/Frame 047201/0377 →
Priority Claims (1)
DK PA201570059 · Feb 2, 2015 · national
Continuity (2)
Division 15543545
Related Publication 20190282545A1 · Sep 19, 2019